Expand KYTX Menu
KYTX MENU

KYTX Latest Press Releases

-- April 9, 2026 --

Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026 Globe Newswire 8:00 AM

-- March 26, 2026 --

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results Globe Newswire 4:02 PM

-- March 5, 2026 --

Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026 Globe Newswire 4:21 PM

-- March 3, 2026 --

Kyverna Therapeutics to Participate in Upcoming March Investor Conferences Globe Newswire 8:00 AM

-- February 24, 2026 --

Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors Globe Newswire 8:00 AM

-- February 3, 2026 --

Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer Globe Newswire 8:00 AM

-- January 12, 2026 --

Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference Globe Newswire 8:00 AM

-- January 5, 2026 --

Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference Globe Newswire 8:00 AM

-- December 17, 2025 --

Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock Globe Newswire 9:24 AM

-- December 15, 2025 --

Kyverna Therapeutics Announces Proposed Public Offering of Common Stock Globe Newswire 4:01 PM
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome Globe Newswire 6:30 AM

-- December 14, 2025 --

Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome Globe Newswire 2:30 PM
Market Data Delayed 15 Minutes